BACKGROUND: AZD8055 is a small molecule ATP-competitive inhibitor of the serine/threonine kinase mTOR that regulates cap-dependent translation through the mTORC1 complex and Akt activation through the mTORC2 complex. Procedures AZD8055 was tested against the PPTP in vitro panel at concentrations ranging from 1.0 nM to 10 µM and against the PPTP in vivo panels at a dose of 20 mg/kg administered orally daily x 7 for 4 weeks. RESULTS: In vitro the median relative IC(50) for AZD8055 against the PPTP cell lines was 24.7 nM. Relative I/O values >0% (consistent with a cytostatic effect) were observed in 8 cell lines and 15 cell lines showed Relative I/O values ranging from -4.7 to -92.2% (consistent with varying degrees of cytotoxic activity). In vivo AZD8055 induced significant differences in EFS distribution compared to controls in 23 of 36 (64%) evaluable solid tumor xenografts, and 1 of 6 evaluable ALL xenografts. Intermediate activity for the time to event activity measure (EFS T/C >2) was observed in 5 of 32 (16%) solid tumor xenografts evaluable. The best response was stable disease. PD2 (progressive disease with growth delay) was observed in 20 of 36 (55.6%) evaluable solid tumor xenografts. AZD8055 significantly inhibited 4E-BP1, S6, and Akt phosphorylation following day 1 and day 4 dosing, but suppression of mTORC1 or mTORC2 signaling did not predict tumor sensitivity. CONCLUSIONS: AZD8055 demonstrated broad activity in vitro, but at the dose and schedule studied demonstrated limited activity in vivo against the PPTP solid tumor and ALL panels.
BACKGROUND:AZD8055 is a small molecule ATP-competitive inhibitor of the serine/threonine kinase mTOR that regulates cap-dependent translation through the mTORC1 complex and Akt activation through the mTORC2 complex. Procedures AZD8055 was tested against the PPTP in vitro panel at concentrations ranging from 1.0 nM to 10 µM and against the PPTP in vivo panels at a dose of 20 mg/kg administered orally daily x 7 for 4 weeks. RESULTS: In vitro the median relative IC(50) for AZD8055 against the PPTP cell lines was 24.7 nM. Relative I/O values >0% (consistent with a cytostatic effect) were observed in 8 cell lines and 15 cell lines showed Relative I/O values ranging from -4.7 to -92.2% (consistent with varying degrees of cytotoxic activity). In vivo AZD8055 induced significant differences in EFS distribution compared to controls in 23 of 36 (64%) evaluable solid tumor xenografts, and 1 of 6 evaluable ALL xenografts. Intermediate activity for the time to event activity measure (EFS T/C >2) was observed in 5 of 32 (16%) solid tumor xenografts evaluable. The best response was stable disease. PD2 (progressive disease with growth delay) was observed in 20 of 36 (55.6%) evaluable solid tumor xenografts. AZD8055 significantly inhibited 4E-BP1, S6, and Akt phosphorylation following day 1 and day 4 dosing, but suppression of mTORC1 or mTORC2 signaling did not predict tumor sensitivity. CONCLUSIONS:AZD8055 demonstrated broad activity in vitro, but at the dose and schedule studied demonstrated limited activity in vivo against the PPTPsolid tumor and ALL panels.
Authors: Thomas E Witzig; Susan M Geyer; Irene Ghobrial; David J Inwards; Rafael Fonseca; Paul Kurtin; Stephen M Ansell; Ronnie Luyun; Patrick J Flynn; Roscoe F Morton; Shaker R Dakhil; Howard Gross; Scott H Kaufmann Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544
Authors: Natalia L M Liem; Rachael A Papa; Christopher G Milross; Michael A Schmid; Mayamin Tajbakhsh; Seoyeon Choi; Carole D Ramirez; Alison M Rice; Michelle Haber; Murray D Norris; Karen L MacKenzie; Richard B Lock Journal: Blood Date: 2004-02-05 Impact factor: 22.113
Authors: H S Friedman; O M Colvin; S X Skapek; S M Ludeman; G B Elion; S C Schold; P F Jacobsen; L H Muhlbaier; D D Bigner Journal: Cancer Res Date: 1988-08-01 Impact factor: 12.701
Authors: Beverly A Teicher; Eric Polley; Mark Kunkel; David Evans; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; John Connelly; Erik Harris; Anne Monks; Joel Morris Journal: Mol Cancer Ther Date: 2015-09-08 Impact factor: 6.261
Authors: A C M van de Luijtgaarden; Y M H Versleijen-Jonkers; M H S Roeffen; H W B Schreuder; U E Flucke; W T A van der Graaf Journal: Target Oncol Date: 2013-01-06 Impact factor: 4.493
Authors: Mamata Singh; Justin M Leasure; Christopher Chronowski; Brian Geier; Kathryn Bondra; Wenrui Duan; Lauren A Hensley; Miguel Villalona-Calero; Ning Li; Anthony M Vergis; Raushan T Kurmasheva; Changxian Shen; Gary Woods; Nikhil Sebastian; Denise Fabian; Rita Kaplon; Sue Hammond; Kamalakannan Palanichamy; Arnab Chakravarti; Peter J Houghton Journal: Clin Cancer Res Date: 2014-04-30 Impact factor: 12.531
Authors: Edward F Attiyeh; John M Maris; Richard Lock; C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Gorlick; E Anders Kolb; Stephen T Keir; Jianrong Wu; Yosef Landesman; Sharon Shacham; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2015-09-23 Impact factor: 3.167
Authors: Jose J Limon; Lomon So; Stefan Jellbauer; Honyin Chiu; Juana Corado; Stephen M Sykes; Manuela Raffatellu; David A Fruman Journal: Proc Natl Acad Sci U S A Date: 2014-11-10 Impact factor: 11.205
Authors: Wei Wei; Qihui Shi; Francoise Remacle; Lidong Qin; David B Shackelford; Young Shik Shin; Paul S Mischel; R D Levine; James R Heath Journal: Proc Natl Acad Sci U S A Date: 2013-03-25 Impact factor: 11.205
Authors: C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Lock; Richard Gorlick; E Anders Kolb; Raushan T Kurmasheva; Stephen T Keir; John M Maris; Catherine A Billups; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2012-09-21 Impact factor: 3.167